Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
about
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinionPharmacokinetic and pharmacodynamic profile of bendamustine and its metabolitesAllogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older PatientsThe Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs EraSystemic Front Line Therapy of Follicular Lymphoma: When, to Whom and HowMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsOutcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature reviewLenalidomide for the treatment of B-cell lymphoma.A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.The clinical development of obinutuzumab for the treatment of follicular lymphoma.Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape.Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose.Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency.Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)Bortezomib in mantle cell lymphoma: comparative therapeutic outcomesMaintenance Therapies in Indolent Lymphomas: should Recent Data Change the Standard of Care?FNC efficiently inhibits mantle cell lymphoma growth.SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma.Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma.Radiotherapy as an effective treatment modality for follicular lymphoma: a single institution experience.Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma.Bendamustine reactivates latent Epstein-Barr virus.Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.Follicular Lymphoma: The Management of Elderly Patient.Current regimens and novel agents for mantle cell lymphoma.Therapeutic approaches in patients with newly diagnosed follicular lymphoma.New therapies in non-Hodgkin lymphoma.A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma.Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.Bortezomib in the treatment of mantle cell lymphoma.Treatment options for mantle cell lymphoma.Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options.Chimeric antigen receptor T-cell therapies for lymphoma.
P2860
Q26783430-D58D7ED7-07B9-496A-A349-943B457443C0Q27011795-4177383F-9F3B-48A7-92FE-21A6C34727E7Q28066710-4ED88B2F-453B-4F72-ACE8-5F42D2ADC9DFQ28072397-8E79DAEB-A0D0-4035-B710-09831C764E2EQ28073262-EBA9EF3B-A1B4-4001-8A48-D0105C27AA42Q28075606-0CFE358E-4AE0-499C-BCAC-1BA52A68C734Q28087748-4A17D778-8F45-4A10-A266-2A2D1B03E62EQ30249007-1854A71A-1399-44F3-B1E7-F2B5DC50DF08Q33424956-663E3F82-7AA4-4CFC-BCBD-666CFE339737Q33425935-A61F1351-F4EE-4705-A8B2-9F75050E7265Q33565265-4E53A176-A2DB-48AB-B184-52E8A40E921DQ33574197-91BAC67D-A800-42F2-8C53-4778611BDBCDQ33621041-56BCD804-29C5-4333-B92B-A7FABF722F0DQ33877999-47E93AD2-7280-4087-A97F-6236969DD0BFQ34480345-61FD23A0-571D-4EE2-933B-CE7D0619680BQ35483796-7F567E2D-AC98-48AC-A579-113248B0FBA8Q35979057-98D42568-CA5F-42D4-81DE-E992375355FEQ36278006-84EB7E3F-1462-40B2-B778-DEE4FF1529D5Q36305803-F2653D52-4729-48FD-A58F-1D6352FC0FAFQ36319779-540DA4B8-57C6-4E07-9D8A-63BD218D8322Q36400279-586306D0-D6BA-4645-A7BF-384A6251B580Q36413919-007A939F-83CE-4226-A521-855FB895791CQ36448074-0D2045AD-D27F-4635-8690-1C3D67F7BE2AQ36456078-BB3D2F64-F4E9-48C0-83B2-EB7EA83836C2Q36934350-1796DBCD-9F6D-4468-BA2D-6B68C2A39A72Q37037432-36CD0354-57C2-40A0-90C5-83A9EC0031A7Q37094781-2954ED19-D519-480C-AD69-5E3C7EB792A1Q37524930-678D9AC7-B756-45E0-9B3C-D15DD804603CQ37577856-916D9D07-9C43-45F9-8B12-9BC6C7FF08E8Q38224186-988C8874-8599-42AF-8DFF-6A064F2231C9Q38267041-C783A2C9-5ECC-4EE5-BEBE-A1ABACCFA862Q38315779-00CBCC65-EEDC-463B-B9A4-D77BA86F2DFDQ38364912-70060824-D194-4CC4-ABBE-6F12B04B4A8DQ38417140-34610632-18AD-4A7C-BEC8-C3851B11E210Q38535489-FA12E60E-FCD3-41A3-BC2F-511A0C84D21FQ38548134-89327A59-7AE0-434C-9062-D74F5640C77DQ38582650-91E07E5D-DCD7-48E5-91C5-5859DD86868AQ38584922-D6EB557C-2F23-417E-956D-D853AA2A5FA9Q38594531-0CCAB7EF-672F-4CBB-9BF8-54A6B581C96EQ38600697-1401CAB6-7F92-4DCB-81F3-3D147C4741EA
P2860
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Randomized trial of bendamusti ...... NHL or MCL: the BRIGHT study.
@ast
Randomized trial of bendamusti ...... NHL or MCL: the BRIGHT study.
@en
Randomized trial of bendamusti ...... NHL or MCL: the BRIGHT study.
@nl
type
label
Randomized trial of bendamusti ...... NHL or MCL: the BRIGHT study.
@ast
Randomized trial of bendamusti ...... NHL or MCL: the BRIGHT study.
@en
Randomized trial of bendamusti ...... NHL or MCL: the BRIGHT study.
@nl
prefLabel
Randomized trial of bendamusti ...... NHL or MCL: the BRIGHT study.
@ast
Randomized trial of bendamusti ...... NHL or MCL: the BRIGHT study.
@en
Randomized trial of bendamusti ...... NHL or MCL: the BRIGHT study.
@nl
P2093
P2860
P1433
P1476
Randomized trial of bendamusti ...... NHL or MCL: the BRIGHT study.
@en
P2093
Brad S Kahl
David Macdonald
David Simpson
Doreen M Hallman
John M Burke
Kathryn Kolibaba
Mark Hertzberg
Michael Craig
Mihaela Munteanu
P2860
P304
P356
10.1182/BLOOD-2013-11-531327
P407
P50
P577
2014-03-03T00:00:00Z